Literature DB >> 1510422

Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin.

B Shasha1, R Lang, E Rubinstein.   

Abstract

Mice infected with Brucella melitensis were treated with streptomycin, co-trimoxazole, ciprofloxacin, doxycycline, and rifampin intraperitoneally and with ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin orally for 14 to 21 days. Doxycycline- and rifampin-treated animals (either route) demonstrated a cure rate significantly better than that of controls. Longer therapy periods were associated with a significantly better outcome. Therapy failure was observed in all mice treated with ciprofloxacin, ofloxacin, and pefloxacin administered orally as well as in mice treated intraperitoneally with ciprofloxacin. Our findings demonstrate that treatment of experimental brucellosis in mice with doxycycline and rifampin yields therapeutic results that are superior to those yielded by treatment with quinolones.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510422      PMCID: PMC188798          DOI: 10.1128/AAC.36.5.973

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Evaluation of prolonged antibiotic therapy in mice with chronic Brucella infection due to Brucella melitensis.

Authors:  J M SHAFFER; C J KUCERA; W W SPINK
Journal:  J Immunol       Date:  1953-01       Impact factor: 5.422

Review 2.  Modern chemotherapy for brucellosis in humans.

Authors:  W H Hall
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  The action of aureomycin and other chemotherapeutic agents in experimental brucellosis.

Authors:  A I BRAUDE; W W SPINK
Journal:  J Immunol       Date:  1950-08       Impact factor: 5.422

4.  [Rifampicin and tetracycline in the treatment of experimental brucellosis in mice].

Authors:  A Philippon; A Kazmierczak
Journal:  Ann Inst Pasteur (Paris)       Date:  1972-09

5.  [Treatment of brucellosis associated with corynebacterium parvum infection in mice with antibiotics (tetracycline, ampicillin, trimethoprim-sulfamethoxazole)].

Authors:  A Philippon; A Kazmierczak; P Névot
Journal:  Ann Inst Pasteur (Paris)       Date:  1972-09

6.  Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis.

Authors:  R Lang; R Raz; T Sacks; M Shapiro
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

7.  [Treatment of experimental brucellosis of mice and guinea pigs by rifampicin].

Authors:  A Philippon; A Kazmierczak; M Plommet; J Marly; P Nevot
Journal:  Dev Biol Stand       Date:  1976

8.  In vitro susceptibility of Brucella melitensis to antibiotics.

Authors:  E Rubinstein; R Lang; B Shasha; B Hagar; L Diamanstein; G Joseph; M Anderson; K Harrison
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides.

Authors:  M W Fountain; S J Weiss; A G Fountain; A Shen; R P Lenk
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

10.  Rifampin in the treatment of experimental brucellosis in mice and guinea pigs.

Authors:  A M Philippon; M G Plommet; A Kazmierczak; J L Marly; P A Nevot
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

  10 in total
  8 in total

1.  Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.

Authors:  Edurne Imbuluzqueta; Carlos Gamazo; Hugo Lana; Miguel Ángel Campanero; David Salas; Ana Gloria Gil; Elisa Elizondo; Nora Ventosa; Jaume Veciana; María J Blanco-Prieto
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 3.  Quinolones in intracellular infections.

Authors:  J C Pechère
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  In vitro activities of new macrolides and rifapentine against Brucella spp.

Authors:  J A García-Rodríguez; J L Muñoz Bellido; M J Fresnadillo; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

Authors:  S P Bonacorsi; M R Scavizzi; A Guiyoule; J H Amouroux; E Carniel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.

Authors:  R Lang; B Shasha; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 7.  Laboratory animal models for brucellosis research.

Authors:  Teane M A Silva; Erica A Costa; Tatiane A Paixão; Renée M Tsolis; Renato L Santos
Journal:  J Biomed Biotechnol       Date:  2011-02-20

8.  Anti-Brucella activity of Caryopteris mongolica Bunge root extract against Brucella melitensis infection in mice.

Authors:  Tsevelmaa N; Narangerel B; Odgerel O; Dariimaa D; Batkhuu J
Journal:  BMC Complement Altern Med       Date:  2018-05-03       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.